Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-203: Pemigatinib Monotherapy in Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
jRCT2080225011Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in Myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1), sponsored by Incyte. Started Jan 2020; status: completed.
02
Drugs
pemigatinib
03
Conditions
Myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1)
Beyond the preview
Go deeper on jRCT2080225011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225011.